18F-FDOPA PET/CT 与 123I-MIBG SPECT/CT 诊断嗜铬细胞瘤和副神经节瘤的前瞻性对比研究
前瞻性单机构对比研究纳入32例疑似或复发/转移性嗜铬细胞瘤和副神经节瘤(PPGL)患者,比较18F-FDOPA PET/CT与123I-MIBG SPECT/CT的诊断效能。基于患者的分析中,18F-FDOPA PET/CT敏感度95.7%非劣于123I-MIBG SPECT/CT的91.3%,特异度均为88.9%。在复发/转移组基于区域的分析中,18F-FDOPA PET/CT敏感度显著更高(86.2% vs 65.5%,P=0.031),观察者间一致性也更好(κ=0.94 vs 0.85)。
要点
- 基于患者分析,18F-FDOPA PET/CT敏感度95.7%非劣于123I-MIBG SPECT/CT的91.3%。
- 两种方法特异度均为88.9%,无显著差异。
- 复发/转移组区域分析中,18F-FDOPA PET/CT敏感度86.2%显著高于123I-MIBG SPECT/CT的65.5%。
核心结论
- 18F-FDOPA PET/CT诊断PPGL的敏感度非劣于123I-MIBG SPECT/CT,特异度相当。
- 在评估PPGL复发和转移时,18F-FDOPA PET/CT在敏感度和观察者间一致性方面均优于123I-MIBG SPECT/CT。
研究设计与样本
- 前瞻性、单机构对比研究,纳入疑似PPGL或显示复发和/或远处转移的PPGL患者。
- 共评估32例患者:初诊组21例中14例最终诊断为PPGL,复发/转移组11例中9例最终诊断为PPGL。
- 最终诊断通过病理或临床随访确立;核医学医师在不知临床数据的情况下进行图像分析。
- 主要目标为确认18F-FDOPA PET/CT诊断敏感度的非劣效性。
主要发现
- 基于患者的分析中,18F-FDOPA PET/CT敏感度95.7%对比123I-MIBG SPECT/CT敏感度91.3%,95%置信区间下限为-10%,在预设非劣效界值-12%之内。
- 两种方法特异度均为88.9%,无显著差异。
- 复发/转移组基于区域的分析中,18F-FDOPA PET/CT敏感度86.2%显著高于123I-MIBG SPECT/CT的65.5%(P=0.031)。
- 观察者间一致性:18F-FDOPA PET/CT的κ=0.94,优于123I-MIBG SPECT/CT的κ=0.85。
- 双相18F-FDOPA PET/CT中加入早期相可轻微改善诊断效能,但未达统计学显著程度。
关键数值与推荐
- 基于患者分析:18F-FDOPA PET/CT敏感度95.7% vs 123I-MIBG SPECT/CT敏感度91.3%,非劣效界值-12%,95%CI下限-10%。
- 基于患者分析:18F-FDOPA PET/CT特异度88.9% vs 123I-MIBG SPECT/CT特异度88.9%,无显著差异。
- 复发/转移组基于区域分析:18F-FDOPA PET/CT敏感度86.2% vs 123I-MIBG SPECT/CT敏感度65.5%(P=0.031)。
- 观察者间一致性:18F-FDOPA PET/CT κ=0.94 vs 123I-MIBG SPECT/CT κ=0.85。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare the diagnostic performances of 18 F-FDOPA PET/CT and 123 I-MIBG scintigraphy with SPECT/CT for detection of pheochromocytoma and paraganglioma (PPGL). PATIENTS AND METHODS: We conducted a prospective, single-institution comparative study. Patients suspected of having PPGL or those showing recurrence and/or distant metastasis of PPGL were enrolled. The primary objective was to affirm the noninferiority of 18 F-FDOPA PET/CT for diagnostic sensitivity. Both 123 I-MIBG scintigraphy with SPECT/CT (at 4 and 24 hours) and 18 F-FDOPA PET/CT (at 5 and 60 minutes after radiotracer administration) were performed. The final diagnosis was established either pathologically or via clinical follow-up. Nuclear physicians, unaware of the clinical data, undertook image analysis. RESULTS: Thirty-two patients were evaluated: 14 of 21 with an initial diagnosis and 9 of 11 with recurrence/metastasis had PPGLs in their final diagnoses. In patient-based analyses, 18 F-FDOPA PET/CT (95.7%) exhibited noninferior sensitivity compared with 123 I-MIBG SPECT/CT (91.3%), within the predetermined noninferiority margin of -12% by a 95% confidence interval lower limit of -10%. Both modalities showed no significant difference in specificity (88.9% vs 88.9%). In the region-based analysis for the recurrence/metastasis group, 18 F-FDOPA PET/CT demonstrated significantly higher sensitivity compared with 123 I-MIBG SPECT/CT (86.2% vs 65.5%, P = 0.031) and superior interobserver agreement (κ = 0.94 vs 0.85). The inclusion of an early phase in dual-phase 18 F-FDOPA PET/CT slightly improved diagnostic performance, albeit not to a statistically significant degree. CONCLUSIONS: 18 F-FDOPA PET/CT demonstrated noninferior sensitivity and comparable specificity to 123 I-MIBG SPECT/CT in the diagnosing PPGL. Notably, in the assessment of PPGL recurrence and metastasis, 18 F-FDOPA PET/CT outperformed 123 I-MIBG SPECT/CT in terms of both sensitivity and interobserver agreement.
引用
- Sung C, Lee HS, Lee DY, et al. A Prospective Comparative Study of 18 F-FDOPA PET/CT Versus 123 I-MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2023. PMID: 38054497. doi:10.1097/RLU.0000000000004963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。